1. Monterrey Venture Capital Conference
ANGEL VENTURES MXICO, S.C.
CLUB DE INVERSIONISTAS DE MXICO, A.C.
BPS-CardiacMedicalDevicebyknavii.
2. BPS-Cardiac: ThePain
People who needs CVBP (Central Venous Blood Pressure
Measurement).
Intensive Care Units (ICU)
Heart attack
Catheterization:Expensive & Risky,Procedure
Potential Problems: Infections, Fluid shifts.
Pain
Val.
Prop.
Tech.
Mkt.
Opp.
Bus.
Mod.
Team
Fin.
Status
3. BPS-Cardiac: ValueProposition
A painless, low cost, technology to measure CVBP.
Stake Holder
Patient and his Family
Physician & Nurse
Payers (Public & Private)
Hospitals
Government Regulator
Value Created
Lessen Pain and suffering
Less en Lawsuitsfor wrong catheterizations.
Reduce the currentCost of the procedure
Increase the productivity (faciilities)
Secure and effective treatments (Law/Reg.)
Pain
Val.
Prop.
Tech.
Mkt.
Opp.
Bus.
Mod.
Team
Fin.
Status
4. BPS-Cardiac: Technology
A disruptive non-invasive technology that measure CVBP (Lab scale
prototype is ready!!!!)
Pain
Val.
Prop.
Tech.
Mkt.
Opp.
Bus.
Mod.
Team
Fin.
Status
5. BPS-Cardiac: TechnologyCompetitiveness
Pain
Val.
Prop.
Tech.
Mkt.
Opp.
Bus.
Mod.
Team
Fin.
Status
6. BPS-Cardiac: MarketOpportunity
PotentialMarket:US Market (ICU Beds)
CAGR 12.3%
Hospitals2
2,754
BPS-Cardicac:
$4,000
$491
MUSD
Beds in Hospitals2
951,045
Intensive Care Beds2
122,810
BCC Research Report Code HLC019D,Published:August 2009
includes, equipment disposal and services.
(2) American Hospital Association: Fast Facts on US Hospitals
2009 report.
Pain
Val.
Prop.
Tech.
Mkt.
Opp.
Bus.
Mod.
Team
Fin.
Status
7. BPS-Cardiac: Business Model
Goal: License the technology to a major Medical Device
Manufacturer
GE Medical Systems
Johnson & Johnson Medical System
Baxter
Where We add value to the Business Model?
Disruptive Technology
Patent
Exclusivity for US/Mexico Markets
Regulatory Compliance
Paperwork
USPTO, FDA, COFEPRIS
Clinical trials
Manufacturing & Testing (1,000 Units)
Pain
Val.
Prop.
Tech.
Mkt.
Opp.
Bus.
Mod.
Team
Fin.
Status
8. BPS-Cardiac: TheTeam
Fernando Huerta
Marco Sanchez
Viridiana Omana
Michele Gonzalez
Pain
Val.
Prop.
Tech.
Mkt.
Opp.
Bus.
Mod.
Team
Fin.
Status
9. BPS-Cardiac: Financials (ValueCreation)
Product
Target Market US/Mex:
Units Solds: 28,179
Revenue: $112M usd
Royalties: $13.5 M usd
NPV @12%:Investors, Founders & MDM: $28.6M usd
Investors:4.0 M usd
Founders: $9.4M usd
Medical Device Manufacturer: 15.2M usd
Payback:
Investors & Founders:3.9 years
Device Manufacter: 1.2 years
Pain
Val.
Prop.
Tech.
Mkt.
Opp.
Bus.
Mod.
Team
Fin.
Status
10. BPS-Cardiac: Funds Required
VC investment in Medical Devices Startups $719MUSD / Q4 2009
$1.56 MUSD
Equity: 30%
Funds used for:
a) Exclusivity (US/Mex)
b) FDA/COFEPRIS Approvals
c) USPTO filing
d) Clinical Trials
e) Manufacturer 1,000 units
f) Due diligence for contracting MDM
Exit: Selling IP to a major Medical
Device Manufacturer.
Pain
Val.
Prop.
Tech.
Mkt.
Opp.
Bus.
Mod.
Team
Fin.
Status
11. BPS-Cardiac: Status
Negotiation:
Medical Dev. Manufacturer (MDM)
Licensing contract signed
MDM Ready for Sale.
Manufacturing1,000 Units
Clinical Trials
FDA/COFEPRIS Approvals
Raise Funds: $1.56 MUSD
IP Filing
US/Mex
Massive
Commercialization
Raising Capital
$1.56 MUSD
R&D
Royalties
2005 2009
2010
2011
2012
2013
Pain
Val.
Prop.
Tech.
Mkt.
Opp.
Bus.
Mod.
Team
Fin.
Status
12. BPS Cardiac: Remember!!!!!!
This is an Excellent Opportunity to invest in a non-invasive low
risk disruptive technology that saves people lives.
Business Upsides: More applications, can be expanded worldwide and
with a potential of developing a recurrent business
disposals.
That requires an investment of $1.56 MUSD used for key success
activities. (IP Lawers and filing and device manufacturing)
And creates an economicvalueof $28.6M USD.
13. BPS-Cardiac: Thanks you!!!!
Information: [email protected]
Mobile: +52 +81 1516-8469
